The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
Median PFS appears to back earlier response rate promise.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Solstice Oncology acquires porustobart from Harbour Biomed.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
